Abbott Hits Hospira With Patent Suit Over Zemplar

Law360, New York (July 22, 2011, 4:30 PM EDT) -- Abbott Laboratories slapped Hospira Inc. with a lawsuit Thursday in Delaware federal court, claiming that Hospira infringed two patents by trying to tap into the market for paricalcitol, which Abbott markets as the kidney disease treatment Zemplar.

The plaintiff claims Lake Forest, Ill.-based Hospira infringed the patents-in-suit when it filed New Drug Application No. 201-657 pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, seeking a green light from the U.S. Food and Drug Administration for three formulations of injectable paricalcitol drug products before the patents' expiration in 2018.

"Abbott will be substantially and irreparably damaged and harmed...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!